- Home
- BCAB vs ELEV Comparison
BCAB vs ELEV Comparison
Compare BCAB & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- ELEV
- Stock Information
- Founded
- BCAB 2007
- ELEV 2019
- Country
- BCAB United States
- ELEV United States
- Employees
- BCAB N/A
- ELEV N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- ELEV Health Care
- Exchange
- BCAB Nasdaq
- ELEV Nasdaq
- Market Cap
- BCAB 27.0M
- ELEV 22.0M
- IPO Year
- BCAB 2020
- ELEV 2021
- Fundamental
- Price
- BCAB $0.47
- ELEV $0.36
- Analyst Decision
- BCAB Buy
- ELEV Buy
- Analyst Count
- BCAB 2
- ELEV 6
- Target Price
- BCAB $1.00
- ELEV $2.94
- AVG Volume (30 Days)
- BCAB 538.8K
- ELEV 996.3K
- Earning Date
- BCAB 05-06-2025
- ELEV 05-16-2025
- Dividend Yield
- BCAB N/A
- ELEV N/A
- EPS Growth
- BCAB N/A
- ELEV N/A
- EPS
- BCAB N/A
- ELEV N/A
- Revenue
- BCAB $11,000,000.00
- ELEV N/A
- Revenue This Year
- BCAB N/A
- ELEV N/A
- Revenue Next Year
- BCAB N/A
- ELEV N/A
- P/E Ratio
- BCAB N/A
- ELEV N/A
- Revenue Growth
- BCAB N/A
- ELEV N/A
- 52 Week Low
- BCAB $0.24
- ELEV $0.22
- 52 Week High
- BCAB $3.53
- ELEV $4.33
- Technical
- Relative Strength Index (RSI)
- BCAB 59.13
- ELEV 55.46
- Support Level
- BCAB $0.44
- ELEV $0.33
- Resistance Level
- BCAB $0.58
- ELEV $0.36
- Average True Range (ATR)
- BCAB 0.06
- ELEV 0.03
- MACD
- BCAB 0.00
- ELEV 0.00
- Stochastic Oscillator
- BCAB 64.11
- ELEV 68.73
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.